Integra LifeSciences announces the release of the PANTA XL Arthrodesis Nail


Integra LifeSciences Holdings Corporation announced the release of the Panta(R) XL Arthrodesis Nail, a solution for tibiotalocalcaneal (TTC) arthrodesis. The Panta(R) XL Nail has received clearance from the U.S.FDA and a CE Mark Certification in the European Union.

Robert Paltridge, President of Integra Extremity Reconstruction said, he Panta(R) XL Arthrodesis nail is an excellent addition to our family of hindfoot products, and expands our hindfoot portfolio to include a nailing system specifically targeted for the treatment of Charcot foot.

The Panta(R) XL Arthrodesis Nail is a complement to the current Panta(R) product line, incorporating longer lengths and a conical extremity shape designed to reduce stress at the proximal tip of the nail. Another highlight of the system is the benefit of nail autodynamization. The proximal edge of the slot maintains compression while allowing dynamization with post-operative weight bearing, providing continuous compression. These product benefits allow for improved treatment of Charcot patients.

The Panta(R) XL Arthrodesis Nail will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.